NAT2 genotyping to personalize tuberculosis treatment has previously been shown to reduce hepatotoxicity and improve culture conversion rate. We show that routine use of NAT2 genotyping would be highly cost-effective in Brazil, South Africa, and India.
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ABSTRACT
Background
There is marked interindividual variability in metabolism and resulting toxicity and effectiveness of drugs used for tuberculosis treatment. For isoniazid, mutations in the N-acetyltransferase-2 (NAT2) gene explain over 88% of pharmacokinetic variability. However, weight-based dosing remains the norm globally. The potential clinical impact and cost-effectiveness of pharmacogenomic-guided therapy (PGT) is unknown.
Methods
We constructed a decision tree model to project lifetime costs and benefits of isoniazid PGT for drug-susceptible tuberculosis in Brazil, South Africa, and India. PGT was modeled to reduce isoniazid toxicity among slow NAT2 acetylators and reduce treatment failure among rapid acetylators. The genotyping test was assumed to cost the same as the GeneXpert test. The main outcomes were costs (2018 USD), quality adjusted life years (QALYs), and incremental costeffectiveness ratios.
Results
In Brazil, PGT gained 19 discounted life years (23 QALYs) and cost $11,064 per 1,000 patients, a value of $476 per QALY gained. In South Africa, PGT gained 15 life years (19 QALYs) and cost $33,182 per 1,000 patients, a value of $1,780 per QALY gained. In India, PGT gained 20 life years (24 QALYs) and cost $13,195 per 1,000 patients, a value of $546 per QALY gained.
One-way sensitivity analyses showed the cost-effectiveness to be robust to all input parameters.
INTRODUCTION
In 2017, there were 10 million tuberculosis (TB) cases and 1.6 million deaths, making TB the leading cause of death by an infectious disease worldwide [1] . The World Health Organization (WHO) has initiated the End TB Strategy, which aims to cut cases by 90% and decrease deaths by 95% by 2035 [2] . Increasing treatment effectiveness and reducing adverse events are important components of achieving this goal.
The global treatment success for patients with TB was 82% in 2016 [1] . Standard treatment for people with drug-susceptible TB (DS-TB) consists of standardized, weight-based doses of isoniazid (INH), rifampicin, pyrazinamide, and ethambutol. Up to 33% of those undergoing treatment develop hepatotoxicity [3] , which is associated with increased costs and, in some studies, substantial mortality up to 27% [4] . As many as 3% of new TB cases experience treatment failure [5] , and between 2-14% relapse within 2 years (See Appendix).
There is substantial evidence that standardized, weight-based dosing leads to variable drug levels, which in turn have been associated with treatment response, toxicities, and acquisition of drug-resistance during TB therapy [6, 7] . The most well-characterized variability in TB drug metabolism is with INH, which is primarily metabolized by N-acetyltransferase-2 (NAT2). Individuals with polymorphisms in NAT2 have altered enzyme activity and can be classified into three phenotypic classes: slow, intermediate, or rapid acetylators. Acetylator level has been shown to explain 88% of the interindividual pharmacokinetic variability in INH levels [8] . NAT2 genotype predicts clinically relevant endpoints as well. Multiple studies have revealed that slow 5 acetylators are at increased risk of drug-induced liver injury from INH [9] . A meta-analysis found that rapid acetylators are at increased risk of treatment failure, relapse, and acquisition of resistance [7] .
While pharmacokinetic data support INH dose adjustments by genotype to achieve target levels [10] , there are limited prospective data on whether such adjustments improve outcomes. One randomized trial of pharmacogenomic (PGx)-guided therapy found a significant reduction in hepatotoxicity in slow-metabolizers who were randomized to a lower dose of INH, as well as a reduction in two-month culture positivity in NAT2 rapid metabolizers who received a higher dose [11] .
Over half of the global population are either slow acetylators or rapid acetylators [12] , meaning that half of all patients are currently receiving non-optimized doses. Acetylator phenotype can be accurately predicted by examining 2-7 single nucleotide polymorphisms (SNPs) in NAT2 [13] .
Advances in molecular diagnostics have made point-of-care SNP-typing possible, but currently there are no rapid molecular diagnostics for NAT2 genotype. A key question facing development of a NAT2 rapid test is whether it would be clinically impactful and cost-effective. Here, we construct a decision-analytic model to project the clinical utility and cost-effectiveness of PGxguided TB treatment in Brazil, South Africa, and India.
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METHODS
Overview and Analytic Framework
We constructed a decision tree model to project health outcomes and costs of PGx-guided therapy, compared with standardized treatment, for patients newly diagnosed with DS-TB. With standard therapy, individuals received a standard dose (5 mg/kg) irrespective of acetylator status.
With PGx-guided therapy, slow metabolizers received lower INH doses (2.5 mg/kg), rapid metabolizers received increased doses (7.5 mg/kg), and intermediate metabolizers received standard doses (5 mg/kg) ( Figure 1 ). We projected costs in 2018 USD and health outcomes in quality adjusted life years (QALYs) and compared strategies by incremental cost-effectiveness ratios (ICERs). We modeled health outcomes and costs based on overall population averages in each setting and did not separately model HIV-infected and HIV-uninfected patient groups.
Model Structure and Assumptions
The decision tree includes branches for toxicity, treatment positivity, treatment failure, and death (Appendix Figure S1 ). Treatment duration for each possible combination was modeled according to treatment guidelines [14, 15] . We assume that all patients had DS-TB at baseline and received 2 months of INH, rifampicin, pyrazinamide, and ethambutol followed by 4 months of INH and rifampicin. Patients who were culture positive at 2 months received 9 total months of treatment.
A fraction of these patients was modeled as failing treatment and requiring 12 total months of treatment. We assumed a fraction of those who failed treatment developed multi-drug resistant (MDR)-TB, requiring costlier treatment with higher mortality (See Appendix). Patients who experienced toxicity and were unable to tolerate treatment upon re-challenge were moved to an 7 alternative regimen, which was conservatively modeled as having the same monthly cost as normal TB treatment but lasting a total of 8 months.
Treatment Outcomes by Acetylator Status
Baseline risks of toxicity, 2-month culture positivity, and treatment failure ( Table 1) were derived from random effects models summarizing recent TB treatment trials (Appendix Figures S2-S4) and reflect the global acetylator distribution, so we adjusted them based on each country's acetylator distribution (Tables 1 and S3 ). We assume, based on data from metaanalyses, that individuals with rapid metabolizer phenotypes are more likely to fail treatments than slow and intermediate metabolizer phenotypes (risk ratio of 2.02) [16] . Conversely, we model INH hepatotoxicity to be more common among slow and intermediate metabolizer phenotypes than rapid metabolizer phenotypes (odds ratios of 3.68 and 1.12, respectively) [9] .
Based on published data, we assume that 99% of slow or rapid acetylator patients receiving PGxguided dosing will achieve drug levels comparable to those of intermediate acetylators on standard dosing [10] , and therefore experience the same risk of toxicity or failure. We modeled PGx testing as correctly identifying acetylators 95% of the time. Those who are misidentified and receive an incorrect dose are at higher risk of toxicity or treatment failure, according to their presumed drug level (See Appendix). We assumed that all other TB medications were given at standard doses.
In our model, patients who receive 6 months of treatment have a 5% risk of death [17] . This 6month probability was converted to a monthly rate to confer additional risk of death to patients 8 who receive more than 6 months of treatment. We calculated years of life gained using the average age of TB onset and average life expectancy for each country (Table 1) .
Costs and Utilities
We took a healthcare perspective for costs. Country-specific costs related to TB treatment were derived from primary costing surveys and were adjusted to 2018 USD using consumer price index deflators [5] . Toxicity increased model costs through higher treatment costs ( [18] [19] [20] .
We measured utility by assignment of QALYs to individuals within a simulated cohort according to published utility weights [21, 22] by multiplying utilities by life years. Future costs and benefits were discounted at 3% per year [23] .
Sensitivity and Scenario Analyses
One-way sensitivity analysis assessed the impact of each input variable on the ICER by varying key parameters according across the confidence intervals of their empirical estimates (Appendix Table S4 ). For parameters without empirical estimates, parameters were varied by 50% in each Downloaded from https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciz1212/5697286 by Richard Blevins on 07 January 2020 direction. Two-way sensitivity analysis assessed the cost-effectiveness of all reported acetylator distributions. We conducted a probabilistic sensitivity analysis using a 10,000 draw Monte Carlo simulation to assess the impact of all the input variables on the ICER (Appendix Table S5 ).
Cost-Effectiveness
We defined ICERs less than 1x per capita GDP to be very cost-effective and less than 3x per capita GDP to be cost-effective [24] . In 2018, per capita GDP for Brazil, South Africa were $8,921, $6,340, and $2016, respectively [25] .
Population Attributable Fraction
Using population of acetylator distributions and odds ratios for outcomes comparing acetylator types, we calculated the population attributable fraction (PAF) of INH for treatment failure and toxicity for Brazil, South Africa, and India, as well as for regional acetylator distributions representative of Africa, Central/South America, Europe, Asia (not including East Asia), and East Asia [26] .
All analyses were conducted using R [27] .
RESULTS
Clinical Impact and Cost-Effectiveness
In Brazil, PGx-guided therapy cost an additional $11,064 per 1,000 individuals with DS-TB while gaining an additional 19 discounted life years (23 QALYs) ( Table 2) 
One-Way Sensitivity Analysis
One-way sensitivity analyses showed the cost-effectiveness of PGx testing was robust to changes in all parameters (Figure 2 ). Results were influenced by the risk ratio comparing treatment failure in rapid vs. intermediate acetylators, but PGx testing was still cost-effective across the risk ratio values considered (Appendix Table S4 ). For the base case, we assumed 99% of rapid and slow acetylators' therapeutic drug levels were "normalized" (i.e., to those of intermediate acetylators). However, even if only 16% were normalized, the ICER would still be below per capita GDP in Brazil. In South Africa and India, 37% and 34% of individuals, respectively, had to have their dose normalized for the ICER to be below per capita GDP (Appendix Figure S5 ).
While our base case assumed PGx testing would correctly identify acetylators 95% of the time, if
the test was only 85% accurate, ICERs would be $646/QALY in Brazil, $2,241/QALY in South Africa, and $618/QALY in India (Appendix Figure S6 ). In Brazil, South Africa, and India, the PGx test could cost eleven, four, and three times as much as similar tests, respectively, and PGx testing would still cost less than per capita GDP (Appendix Figure S7 ).
Two-Way Sensitivity Analysis
The benefits of PGx-testing were primarily driven by rapid acetylators and their risk of prolonged culture positivity and treatment failure. Regions with many rapid acetylators, like East Asia, benefited the most from PGx-testing ( Figure 3 ). However, even in Africa, Asia, and Europe where there are more slow than rapid acetylators, PGx-guided therapy would cost <$1,000/QALY assuming similar costs as in Brazil (Appendix Figures S8-S11 ).
Probabilistic Sensitivity Analysis
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In our probabilistic sensitivity analysis, we found PGx-guided therapy to cost less than per capita GDP in 99% of simulations (Figure 4 , Appendix Figure S12 ). PGx-testing was costsaving in some simulations for Brazil and India.
Acetylator Distribution Variability and Population Attributable Fraction
Acetylator distributions vary widely by geographic location, which drives differences in the PAF of adverse events from INH ( Figure 5 ). While Europe, Africa, Asia, Brazil, and India have many slow acetylators, East Asia has many rapid acetylators. In Brazil, 12% of treatment failures and 33% of hepatotoxicity events were attributable to INH dosing that was not optimized for NAT2 status. In South Africa, these PAFs were 12% and 29% while in India they were 12% and 40% ( Figure 5 ). 
DISCUSSION
Although treatment for DS-TB is generally effective, toxicity and failure occur in a substantial minority of patients, causing additional healthcare costs, morbidity, and mortality [28, 29] .
Observational studies and one randomized trial indicate that pharmacogenomic-guided dosing could minimize risks of drug-induced hepatitis and treatment failure. However, if effective, it was previously unclear whether such testing could be cost-effective in countries with high TB burdens where resources are often constrained. Using a model of TB treatment and costs, we find PGx testing to be highly cost-effective even with conservative estimates about its impact on drug-induced hepatitis and response to therapy.
The results supporting the use of PGx testing were robust to all input variables. The primary driver of cost-effectiveness was the failure risk ratio, which determined how effective PGx testing was at averting treatment failure for rapid acetylators. Notably, the PGx test could cost eleven times as much as similar tests on the market and the cost per QALY gained would remain less than per capita GDP in Brazil, which is considered a "very cost-effective" intervention [24] .
In South Africa and India, it could cost four and three times as much, respectively, and still be less than per capita GDP. Our model only accounted for variable costs of PGx testing, not the fixed cost of implementation, which is likely to vary by country. However, similar to GeneXpert, over a 10-year horizon these upfront costs will be far outweighed by the cost of the consumables and personnel time.
Our main analysis found PGx testing to be cost-effective in Brazil, South Africa, and India.
Patients on PGx-guided treatment were less likely to require additional months of treatment and were less likely to experience a toxic event. This resulted in reduced morbidity and mortality as well as fewer additional costs associated with clinic visits, laboratory testing, and therapy modifications. Although we modeled INH-hepatotoxicity to occur in 7% of patients, other studies have found the incidence of INH-induced hepatotoxicity to be as high as 33% [3, 4] , so our model likely underestimates the harms of INH-induced hepatotoxicity and the benefits of PGx dosing. Likewise, we used a conservative value (2.02, [16] ) for the odds ratio comparing culture positivity between rapid and slow acetylators whereas some studies have found an odds ratio as high as 3.47 [11] , which would have increased the benefits of PGx-dosing.
In the absence of an available diagnostic for NAT2 genotype, we assumed that PGx-testing correctly identifies acetylator phenotypes 95% of the time. Under this assumption, intermediate acetylators experienced increased costs and decreased QALYs on PGx-guided therapy because they had a 5% risk of receiving non-optimized dosing. However, the benefits of PGx-guided therapy to slow and rapid acetylators far outweighed the deleterious effect on intermediate acetylators. We believe this assumption of accuracy may be conservative; the one FDA-approved pharmacogenetic test has been found to have near 100% sensitivity and specificity [30] , though it only measures a single nucleotide variant, whereas the NAT2 phenotype is determined by 7 variants. Even when the test was only modeled to be 85% accurate, the test was still very costeffective (Brazil: $646/QALY; South Africa: $2241/QALY; India: $618/QALY).
We did not incorporate transmission effects in this model, as we presumed that individuals who are in treatment programs for DS-TB are unlikely to contribute substantially to transmission.
Likewise, we did not account for the possibility that lower toxicity rates could improve medication adherence and thereby improve outcomes.
These results should be interpreted with consideration of the limitations of the model. Regarding clinical effectiveness, we assumed that PGx-guided therapy would reduce toxicity and improve treatment response to that of intermediate acetylators in 99% of patients. This assumption was based on empiric data from pharmacokinetic studies showing that all slow and fast acetylators receiving the modified doses used in our model achieve drug levels comparable to those of intermediate acetylators under standard dosing [10] . We examined this assumption using broad sensitivity analyses; even when the reduction in risk was just 16% in Brazil, 37% in South Africa, and 34% in India, the ICER was still less than per capita GDP. Additionally, our model does not account for INH monoresistance. Resistance to both INH and rifampicin occurs in 3.5% of new TB cases while 7.9% of new cases have INH monoresistance [1] . However, GeneXpert, the widely used test for drug susceptibility, only tests for rifampicin resistance. Therefore, some patients who test "drug-susceptible" will actually have INH-resistant TB and may not observe any of the benefits of PGx-guided therapy.
The generalizability of these results mainly depends on treatment costs and acetylator distributions. PGx testing is likely to be cost-effective in countries that have comparable or higher treatment costs and per capita GDP as the countries analyzed. Further analyses are needed to evaluate this in countries with fewer resources. The cost-effectiveness of PGx testing was robust to the proportion of the population that are fast or slow acetylators, across broad ranges representative of the global distribution ( Figure 3 ). Additional trials testing the clinical effects of PGx testing would bolster the predictive accuracy of our model.
Despite being cost-effective, PGx testing has not been widely deployed and no company currently manufactures a test. Reasons for delayed adoption may include insufficient clinical evidence about the efficacy of modified doses, reluctance to implement "personalized" approaches to a disease traditionally treated by a public health approach, and the assumption that PGx testing would be too expensive.
Implementing PGx-guided therapy appears highly cost-effective even in resource-constrained settings under conservative assumptions about its impact. In order to be cost-effective, PGx testing only has to be moderately effective at reducing hepatitis and improving treatment response relative to standard dosing; observational data and one randomized trial indicate that the impact on both may be substantial. Future studies should be undertaken to replicate the randomized trial data and evaluate real-world clinical effectiveness of PGx-guided TB treatment in other populations. If confirmed, this approach has the potential to reduce morbidity and improve treatment outcomes substantially for TB globally. 
Utilities
No Infection 1.00 [22] Active TB 0.67 (0.776-0.546) [22] Severe Toxicity 0.67 (+/-0.05) [21] Mild Toxicity 0.91 (+/-0.01) [21] Death 0.00 --Downloaded from https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciz1212/5697286 by Richard Blevins on 07 January 2020 Under standard therapy, all patients with drug susceptible TB receive INH dosed at 5mg/kg. However, slow acetylator types have a higher risk of toxicity (pink) and rapid acetylator types have a higher risk of treatment failure (blue) with this dosage. Using pharmacogenomic-guided dosing, slow acetylators receive 2.5mg/kg and rapid acetylators receive 7.5mg/kg, which optimizes their side effects and treatment efficacy (green).
Figure 2: One-Way Sensitivity Analyses of Key Model Parameters on Incremental Costeffectiveness Ratios (ICERs).
Only parameters found to be most influential on the ICER are presented. Red bars represent an increase in the parameter value, while blue bars represent a decrease in the parameter value. The cost-effectiveness of PGx was robust to all inputs in both Brazil, South Africa, and India. 
